Patient self-testing of white blood cell count and differentiation: A study of feasibility and measurement performance in a population of Danish cancer patients
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Objective: Patients in anticancer treatment with a known side effect of neutropenia are monitored closely with laboratory measurements of white blood cell count (WBC) and differentiation. This study sought to evaluate measurement properties and feasibility of patients' self-testing using a point-of-care testing (POCT) device. Methods: A prospective feasibility and measurement study comparing the standard measurement of cancer patients' WBC and neutrophil count with POCT measurements. The study included 60 outpatients and 22 inpatients from a department of oncology at a university hospital. Results: Patients successfully conducted 106 measurements using the POCT device. 46% of the patients were >70 years. Weighted Deming regression analysis showed minimal yet significant proportional bias between methods, with POCT increasingly underestimating both total WBC and neutrophils compared with the standard method the higher the count. Over 90% of patients reported they were willing and considered themselves able to use the POCT device at home. Conclusions: The instrument can be used for self-testing of post-anticancer leukopenia and has sufficient measurement precision for patient risk stratification. Patients are able and willing to conduct measurements including when in a situation of acute illness. Further studies are needed to confirm safety and value within patients’ own home.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | e13189 |
| Tidsskrift | European Journal of Cancer Care |
| Vol/bind | 29 |
| Udgave nummer | 1 |
| Antal sider | 11 |
| ISSN | 0961-5423 |
| DOI | |
| Status | Udgivet - 2020 |
Bibliografisk note
Funding Information:
The study was conducted at the Department of Oncology, Odense University Hospital, Denmark, covering the Region of Southern Denmark, one of five highly specialised oncology departments in Denmark with 3,600 admissions and 126,000 ambulatory visits annually (2016). The hospital is part of the Danish tax‐funded universal healthcare system. The study was approved by the National Committee on Health Research Ethics project (id S‐20160184) and the Danish Data Protection Agency via the Region of Southern Denmark (id 2012‐58‐0018). The study was performed in accordance with the Declaration of Helsinki.
Funding Information:
Funding information The study is part of Innovative High Technology Cancer Treatment Denmark-Germany (InnoCan) a project funded by Interreg Deutschland-Denmark and the Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital. Phillips Home Clinical Monitoring provided the HemoCue? WBC DIFF units. The authors want to thank the staff from the Design School Kolding and the staff from the local laboratory at the Department of Oncology, Odense University Hospital for their advice and assistance in collection the blood samples and their advice on the development of patient information material. Also, a great thank to the staff from the University College Absalon, Naestved for their assistance with collecting the observational data.
Publisher Copyright:
© 2019 John Wiley & Sons Ltd
ID: 269909470